SCHEMBL6157401

SCHEMBL6157401

O=C(O)CC/C(=N\OCc1ccc(OCc2cn3ccccc3n2)cc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.61
PPARG P37231 1/20 0.55
PPARA Q07869 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
LMNA P02545 1/20 0.52
PDE10A Q9Y233 1/20 0.49
TDP1 Q9NUW8 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.43
ALOX5 P09917 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6157407 1.00 KDM4E (0.61) KDM4EPPARGPPARASMN1; SMN2ALDH1A1
SCHEMBL6157404 1.00 KDM4E (0.61) KDM4EPPARGPPARASMN1; SMN2ALDH1A1
SCHEMBL6160085 0.91 KDM4E (0.57) KDM4EPPARGPPARASMN1; SMN2ALDH1A1
SCHEMBL6160097 0.91 KDM4E (0.57) KDM4EPPARGPPARASMN1; SMN2ALDH1A1
SCHEMBL6160092 0.91 KDM4E (0.57) KDM4EPPARGPPARASMN1; SMN2ALDH1A1
SCHEMBL6157365 0.84 PPARA (0.53) KDM4EPPARGPPARARAB9AALOX5
SCHEMBL6157371 0.84 PPARA (0.53) KDM4EPPARGPPARARAB9AALOX5
SCHEMBL6157375 0.84 PPARA (0.53) KDM4EPPARGPPARARAB9AALOX5
SCHEMBL6158801 0.84 PPARA (0.56) KDM4EPPARGPPARARAB9AALOX5
SCHEMBL6158807 0.84 PPARA (0.56) KDM4EPPARGPPARARAB9AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924300-B2 Oxyiminoalkanoic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
EP-1077957-B1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-08-04 EP disclosed
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP disclosed
CN-1148361-C Oxyiminoalkanoic acid derivatives ����ҩƷ��ҵ��ʽ���� 2004-05-05 CN disclosed
US-20030186985-A1 Oxyiminoalkanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
CN-1300285-A Hydroxyiminoalkanoic Acid Derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-06-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186985-A1 Oxyiminoalkanoic acid derivatives GPR119, IRS1, CPT1A KDM4E 1277/4885PPARG 401/4885PPARA 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.